Insider trade

CEO sold ~$513K of HALO shares in the open market

Traded Mar 4, 2026 · Filed Mar 4, 2026

Why it stands out

The CEO of Halozyme sold $513K of Halozyme shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEO$500K–$1MPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$512,620

Shares × reported transaction price

Timing vs results

15 days after results of Feb 17, 2026, 68 days before results of May 11, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−5.6%	−2.2%	−3.4%
30 days	−6.3%	−3.3%	−3.1%
90 days	+3.6%	+10.7%	−7.0%
180 days	+59.9%	+11.8%	+48.1%

Past results only. Not a forecast.

The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.
Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.400 to $70.390. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.